- Home
- MHN vs CERS Comparison
MHN vs CERS Comparison
Compare MHN & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHN
- CERS
- Stock Information
- Founded
- MHN 1997
- CERS 1991
- Country
- MHN United States
- CERS United States
- Employees
- MHN N/A
- CERS N/A
- Industry
- MHN Investment Bankers/Brokers/Service
- CERS EDP Services
- Sector
- MHN Finance
- CERS Technology
- Exchange
- MHN Nasdaq
- CERS Nasdaq
- Market Cap
- MHN 293.6M
- CERS 276.0M
- IPO Year
- MHN N/A
- CERS 1997
- Fundamental
- Price
- MHN $10.30
- CERS $1.66
- Analyst Decision
- MHN
- CERS Buy
- Analyst Count
- MHN 0
- CERS 1
- Target Price
- MHN N/A
- CERS $4.00
- AVG Volume (30 Days)
- MHN 59.2K
- CERS 1.2M
- Earning Date
- MHN 01-01-0001
- CERS 11-06-2025
- Dividend Yield
- MHN 4.17%
- CERS N/A
- EPS Growth
- MHN N/A
- CERS N/A
- EPS
- MHN N/A
- CERS N/A
- Revenue
- MHN N/A
- CERS $199,191,000.00
- Revenue This Year
- MHN N/A
- CERS $19.07
- Revenue Next Year
- MHN N/A
- CERS $12.03
- P/E Ratio
- MHN N/A
- CERS N/A
- Revenue Growth
- MHN N/A
- CERS 13.03
- 52 Week Low
- MHN $8.69
- CERS $1.12
- 52 Week High
- MHN $10.81
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- MHN 48.49
- CERS 56.81
- Support Level
- MHN $10.22
- CERS $1.38
- Resistance Level
- MHN $10.36
- CERS $1.78
- Average True Range (ATR)
- MHN 0.08
- CERS 0.10
- MACD
- MHN -0.03
- CERS 0.01
- Stochastic Oscillator
- MHN 28.57
- CERS 65.00
About MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.